title: [Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer].
abstract: OBJECTIVE
  To investigate the efficacy and toxicity of recombinant humanized anti-Her-2/neu antibody (Herceptin) and Taxol for patients with Her-2/neu overexpressing metastatic breast cancer.
  
  
  METHODS
  Sixty patients with Her-2/neu overexpressing metastatic breast cancer were investigated. Of the 60 cases, 22 were treated with Herceptin and Taxol and 38 with Taxol and doxorubicin.
  
  
  RESULTS
  The total response rate (RR) of Herceptin and Taxol was 68.2%, and that of Taxol and doxorubicin was 44.7%. The RR of patients with Her-2/neu(+++) was 75%, while that of patients with Her-2/neu(++) was 50%. The major adverse effects were gastro-intestinal tract reactions, myopathy, bone marrow suppression and alopecia.
  
  
  CONCLUSIONS
  The treatment with Herceptin and Taxol is effective and safe for patients with Her-2/neu overexpressing metastatic breast cancer. The therapeutic effect is related to the degree of Her-2/neu overexpression.
authors.affiliation: Department of Oncology, Nanfang Hospital, The First Military Medical University, Guangzhou 510515, China.
authors.forename: Rong-cheng
authors.initials: RC
authors.lastname: Luo
authors.forename: Ai-min
authors.initials: AM
authors.lastname: Li
authors.forename: Jun-yi
authors.initials: JY
authors.lastname: Zhang
authors.forename: Wang-jun
authors.initials: WJ
authors.lastname: Liao
authors.forename: Chen-yang
authors.initials: CY
authors.lastname: Ji
authors.forename: Jing-xia
authors.initials: JX
authors.lastname: Miao
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab